Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2006

View Archived Issues

Snapshots of newly reported clinical trials in leukemia, myelodysplastic syndromes: I

PEP-005 activates neutrophils to reduce residual tumor cells

Progress in phase II study of bremelanotide in female sexual dysfunction

MBX-2044 begins proof-of-concept phase IIa study for diabetes

Heplisav begins pivotal phase III study for hepatitis B

Hana requests SPA for pivotal Marqibo study in ALL

Altus and Genentech sign agreement for ALTU-238

Kosan and Pfizer sign worldwide license agreement for motilin agonist program

Enrollment completed in phase II study of faropenem for acute otitis media

APF-530 NDA filing delayed

EndoTAG-1 shows good safety and preliminary efficacy in pancreatic cancer

Proellex improves bleeding and pain in uterine fibroid patients

NCI begins new studies of ispinesib

iCo files IND for iCo-007 for the treatment of eye diseases

Tibotec files to begin phase I testing of HCV NS3/4A protease inhibitor

GSK to acquire Praecis

NS-2359 begins phase II development for major depressive disorder

Panacos files IND for second-generation HIV maturation inhibitor PA-1050040

Safety, tolerability and efficacy of single- and multiple-dose norclozapine shown in phase II trials

L-type calcium channel modulator MEM-1003 enhances cognitive activity in rodents

Mycamine sNDA filed for candidemia and Candida infections

New agents for cancer covered in recent patent literature

Approvable letter for Altabax in secondarily infected traumatic lesions

Xcytrin filed for NSCLC patients with brain metastases

Byetta receives FDA approval

Recent patents report novel therapeutic agents for asthma, allergy, etc.

Junovan NDA accepted for review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...